MCID: SRC001
MIFTS: 32

Sarcomatoid Mesothelioma

Categories: Cancer diseases

Aliases & Classifications for Sarcomatoid Mesothelioma

MalaCards integrated aliases for Sarcomatoid Mesothelioma:

Name: Sarcomatoid Mesothelioma 12 15 17 71
Malignant Fibrous Mesothelioma 12
Spindled Mesothelioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4488
NCIt 49 C45655
SNOMED-CT 67 399477001
UMLS 71 C0334513

Summaries for Sarcomatoid Mesothelioma

MalaCards based summary : Sarcomatoid Mesothelioma, also known as malignant fibrous mesothelioma, is related to benign mesothelioma and malignant epithelial mesothelioma. An important gene associated with Sarcomatoid Mesothelioma is CALB2 (Calbindin 2), and among its related pathways/superpathways are Cytoskeletal Signaling and Cytoskeleton remodeling Neurofilaments. Affiliated tissues include lung, t cells and spinal cord, and related phenotypes are cardiovascular system and muscle

Related Diseases for Sarcomatoid Mesothelioma

Diseases related to Sarcomatoid Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 307, show less)
# Related Disease Score Top Affiliating Genes
1 benign mesothelioma 31.2 WT1 THBD KRT5 CALB2
2 malignant epithelial mesothelioma 30.8 THBD CALB2
3 rare tumor 30.5 DES ACTC1
4 lymphohistiocytoid mesothelioma 30.5 THBD CDKN2A CALB2
5 fibrous histiocytoma 30.5 VIM DES ACTC1
6 lung sarcoma 30.5 NKX2-1 NAPSA CALB2
7 thymoma 30.2 NKX2-1 MUC1 CDKN2A CALB2
8 malignant fibrous histiocytoma 30.2 VIM MUC1 DES ACTC1
9 fibromatosis 30.0 VIM DES ACTC1
10 spindle cell sarcoma 30.0 VIM MUC1 DES ACTC1
11 sarcoma, synovial 29.9 WT1 VIM MUC1 DES CALB2
12 adenocarcinoma 29.9 NKX2-1 NAPSA MUC4 MUC1 CDKN2A
13 spindle cell carcinoma 29.7 VIM MUC1 KRT5 DES ACTC1
14 asbestosis 29.4 WT1 THBD MUC1 MSLN CALB2
15 peritoneal mesothelioma 29.4 WT1 VIM THBD MUC1 CDKN2A CALB2
16 pericardial mesothelioma 29.3 VIM S100A1 MUC1 KRT5 CALB2
17 sarcoma 29.2 WT1 VIM S100A1 MUC1 DES ACTC1
18 fibroma 29.1 VIM S100A1 DES CALB2 ACTC1
19 benign peritoneal mesothelioma 29.0 WT1 PDPN MUC1 MSLN KRT5 CALB2
20 malignant pleural mesothelioma 28.8 WT1 THBD PDPN NKX2-1 MUC1 MSLN
21 leiomyosarcoma 28.4 WT1 VIM S100A1 MUC1 DES CDKN2A
22 mesothelioma, malignant 26.9 WT1 VIM THBD PDPN NKX2-1 MUC1
23 fallopian tube carcinosarcoma 10.5 WT1 CALB2
24 gynandroblastoma 10.5 VIM CALB2
25 rete testis neoplasm 10.5 NKX2-1 CALB2
26 rete testis adenocarcinoma 10.5 NKX2-1 CALB2
27 epididymal neoplasm 10.5 WT1 CALB2
28 testicular gonadoblastoma 10.5 WT1 VIM
29 wolffian duct adenocarcinoma 10.5 WT1 CALB2
30 ovarian brenner tumor 10.5 WT1 THBD
31 juvenile type testicular granulosa cell tumor 10.5 WT1 CALB2
32 fallopian tube squamous cell carcinoma 10.5 WT1 CDKN2A
33 testicular granulosa cell tumor 10.5 WT1 CALB2
34 ovarian endometrioid stromal sarcoma 10.5 WT1 CALB2
35 nodular hidradenoma 10.5 VIM MUC1
36 ovarian gonadoblastoma 10.5 WT1 CALB2
37 ovarian germ cell teratoma 10.5 NKX2-1 CALB2
38 hobnail hemangioma 10.5 WT1 PDPN
39 ovarian seromucinous carcinoma 10.4 WT1 CDKN2A
40 localized pulmonary fibrosis 10.4 PDPN MUC1
41 esophageal adenoid cystic carcinoma 10.4 VIM PDPN
42 ovarian sex-cord stromal tumor 10.4 WT1 CALB2
43 thyroid angiosarcoma 10.4 THBD NKX2-1
44 colonic lymphangioma 10.4 PDPN MUC1
45 vulvar eccrine porocarcinoma 10.4 MUC1 CDKN2A
46 ameloblastic carcinoma 10.4 VIM CDKN2A
47 mucinous cystadenofibroma 10.4 NAPSA MUC1
48 ovarian serous cystadenofibroma 10.4 MUC1 CALB2
49 lymphangiectasis 10.4 VIM ACTC1
50 anaplastic ependymoma 10.4 VIM MUC1
51 mucinous lung adenocarcinoma 10.4 NKX2-1 NAPSA
52 peritoneal serous adenocarcinoma 10.4 WT1 NKX2-1 CALB2
53 appendix disease 10.4 MUC1 CALB2
54 krukenberg carcinoma 10.4 NAPSA MUC1
55 intravascular papillary endothelial hyperplasia 10.4 VIM ACTC1
56 gallbladder adenoma 10.4 PDPN CDKN2A
57 bile duct mucinous adenocarcinoma 10.4 MUC4 MUC1
58 papillary serous adenocarcinoma 10.4 WT1 NKX2-1 CALB2
59 lung papillary adenocarcinoma 10.4 NKX2-1 NAPSA
60 glomangiomyoma 10.4 VIM ACTC1
61 endosalpingiosis 10.4 WT1 MUC1 CALB2
62 penile benign neoplasm 10.4 PDPN CDKN2A
63 clear cell ependymoma 10.4 VIM MUC1
64 atypical neurofibroma 10.4 PDPN CDKN2A
65 olfactory neuroblastoma 10.4 VIM NKX2-1 CALB2
66 tumor of exocrine pancreas 10.4 MUC1 CDKN2A
67 lymphangitis 10.4 PDPN NKX2-1
68 monophasic synovial sarcoma 10.3 VIM MUC1 CALB2
69 chronic ethmoiditis 10.3 MUC4 MUC1
70 supraglottis cancer 10.3 PDPN CDKN2A
71 benign teratoma 10.3 NKX2-1 MUC1 CALB2
72 fallopian tube endometrioid adenocarcinoma 10.3 CDKN2A CALB2
73 thymic carcinoma 10.3 NKX2-1 MUC1 CALB2
74 angiocentric glioma 10.3 VIM ACTC1
75 rhabdoid meningioma 10.3 VIM BAP1
76 epithelioid sarcoma 10.3 VIM MUC1 CALB2
77 sinonasal undifferentiated carcinoma 10.3 MUC1 CEACAM3
78 aggressive digital papillary adenocarcinoma 10.3 MUC1 CEACAM3
79 epithelioid hemangioendothelioma 10.3 CALB2 ACTC1
80 filamentary keratitis 10.3 MUC4 MUC1
81 lung leiomyosarcoma 10.3 KRT5 CALB2
82 appendix cancer 10.3 MUC1 CALB2
83 ovarian serous carcinoma 10.3 WT1 CDKN2A CALB2
84 limbal stem cell deficiency 10.3 MUC4 MUC1
85 infantile digital fibromatosis 10.3 VIM DES
86 cystic teratoma 10.3 NKX2-1 CDKN2A CALB2
87 ureter adenocarcinoma 10.3 NKX2-1 KRT5
88 spermatic cord cancer 10.3 WT1 KRT5
89 papillary adenocarcinoma 10.3 VIM NKX2-1 MUC1
90 microinvasive cervical squamous cell carcinoma 10.3 WT1 KRT5
91 primitive neuroectodermal tumor of the cervix uteri 10.3 VIM DES
92 thymus basaloid carcinoma 10.3 NKX2-1 KRT5
93 lymphangiomatosis 10.3 VIM DES
94 mucinous tubular and spindle renal cell carcinoma 10.3 MUC4 MUC1
95 keratocystic odontogenic tumor 10.3 PDPN CALB2
96 secretory meningioma 10.3 VIM MUC1
97 ovarian cystadenocarcinoma 10.3 MUC1 CDKN2A CALB2
98 endometrial mucinous adenocarcinoma 10.3 VIM MUC1 CDKN2A
99 colon leiomyosarcoma 10.3 WT1 KRT5
100 bizarre leiomyoma 10.3 CDKN2A ACTC1
101 congenital epulis 10.3 VIM DES
102 epulis 10.3 VIM DES
103 lipid-rich breast carcinoma 10.3 MUC1 KRT5
104 combined thymoma 10.3 PDPN KRT5
105 esophageal neuroendocrine tumor 10.3 MUC1 KRT5
106 acral lentiginous melanoma 10.3 VIM MUC1 CDKN2A
107 ewing sarcoma of bone 10.3 VIM DES
108 penile urethral cancer 10.3 KRT5 CDKN2A
109 middle ear adenoma 10.3 MUC1 KRT5
110 collecting duct carcinoma 10.3 VIM MUC1 CDKN2A
111 horseshoe kidney 10.3 NKX2-1 CALB2 ACTC1
112 inverted transitional papilloma 10.3 KRT5 CDKN2A
113 hemangioblastoma 10.3 VIM PDPN MUC1
114 malignant peritoneal mesothelioma 10.3 MUC1 CDKN2A BAP1
115 odontoma 10.2 VIM KRT5
116 nephrogenic adenoma 10.2 S100A1 MUC1
117 male urethral cancer 10.2 KRT5 CDKN2A
118 bladder clear cell adenocarcinoma 10.2 WT1 NAPSA CDKN2A
119 endometrial adenocarcinoma 10.2 VIM MUC1 CDKN2A
120 chordoid glioma 10.2 NKX2-1 MUC1
121 merkel cell carcinoma 10.2 NKX2-1 MUC1 CDKN2A
122 sertoli-leydig cell tumor 10.2 WT1 THBD MUC1 CALB2
123 ovarian germ cell cancer 10.2 NKX2-1 CALB2
124 cystic lymphangioma 10.2 PDPN CALB2
125 thymus adenocarcinoma 10.2 NAPSA KRT5
126 myoepithelial carcinoma 10.2 VIM MUC1 ACTC1
127 cutaneous adenocystic carcinoma 10.2 NKX2-1 KRT5
128 cystadenoma 10.2 MUC1 CEACAM3 CALB2
129 dendritic cell tumor 10.2 VIM MUC1 ACTC1
130 nasal cavity olfactory neuroblastoma 10.2 NKX2-1 KRT5
131 endocervical carcinoma 10.2 VIM NAPSA CDKN2A
132 sertoli cell tumor 10.2 WT1 VIM MUC1 CALB2
133 nephrogenic adenoma of the urethra 10.2 THBD KRT5 CALB2
134 urethral benign neoplasm 10.2 THBD KRT5 CALB2
135 fibroblastic rheumatism 10.2 DES ACTC1
136 liver leiomyosarcoma 10.2 WT1 KRT5 CALB2
137 embryonal sarcoma 10.2 VIM DES
138 papillary squamous carcinoma 10.2 KRT5 CDKN2A
139 eccrine papillary adenocarcinoma 10.2 PDPN KRT5
140 adenomyoma 10.2 MUC4 MUC1 CDKN2A
141 pleomorphic carcinoma 10.2 VIM PDPN NKX2-1 CALB2
142 heart cancer 10.2 WT1 KRT5 CALB2
143 thymus clear cell carcinoma 10.2 NKX2-1 KRT5 CALB2
144 mucinous stomach adenocarcinoma 10.2 NKX2-1 KRT5 CALB2
145 colorectal adenocarcinoma 10.2 NKX2-1 MUC1 CDKN2A
146 lymphangioma 10.2 VIM PDPN ACTC1
147 ovarian serous cystadenocarcinoma 10.2 MUC1 CDKN2A CALB2
148 middle ear carcinoma 10.2 WT1 KRT5
149 breast secretory carcinoma 10.2 MUC4 KRT5
150 spindle cell thymoma 10.2 MUC1 DES CALB2
151 mixed cell type cancer 10.2 WT1 KRT5 CALB2
152 adenoid squamous cell carcinoma 10.2 VIM KRT5
153 adult cystic nephroma 10.2 DES ACTC1
154 pulmonary vein stenosis 10.1 DES ACTC1
155 intraneural perineurioma 10.1 S100A1 MUC1
156 cholecystitis 10.1 MUC4 MUC1 CDKN2A
157 breast osteosarcoma 10.1 WT1 KRT5
158 necrotizing sialometaplasia 10.1 KRT5 ACTC1
159 angiosarcoma 10.1 VIM PDPN MUC1 CALB2
160 mediastinal cancer 10.1 NKX2-1 KRT5
161 botryoid rhabdomyosarcoma 10.1 DES ACTC1
162 small cell carcinoma 10.1 WT1 NKX2-1 MUC1 CDKN2A
163 intrahepatic cholangiocarcinoma 10.1 MUC4 MUC1 BAP1
164 eccrine porocarcinoma 10.1 VIM MUC1 KRT5
165 biphasic synovial sarcoma 10.1 VIM MUC1 DES
166 uterus leiomyosarcoma 10.1 NKX2-1 KRT5
167 esophagus sarcoma 10.1 PDPN KRT5
168 hidradenoma 10.1 VIM MUC1 KRT5
169 osteofibrous dysplasia 10.1 VIM MUC1 KRT5
170 malignant spiradenoma 10.1 KRT5 CDKN2A CALB2
171 mesenchymal chondrosarcoma 10.1 VIM MUC1 DES
172 mucinous adenocarcinoma 10.1 VIM NKX2-1 MUC1 CDKN2A
173 laryngeal small cell carcinoma 10.1 NKX2-1 KRT5 CDKN2A
174 fibrous meningioma 10.1 VIM MUC1
175 cholangiolocellular carcinoma 10.1 MUC1 CDKN2A
176 plasmablastic lymphoma 10.1 MUC1 DES CDKN2A
177 large cell carcinoma 10.1 NKX2-1 MUC1 KRT5
178 ovarian fibrothecoma 10.1 DES CALB2 ACTC1
179 proximal spinal muscular atrophy 10.1 MUC1 DES
180 granulosa cell tumor of the ovary 10.1 VIM CEACAM3 ACTC1
181 central epithelioid sarcoma 10.1 VIM KRT5
182 papillary tumor of the pineal region 10.1 VIM S100A1 MUC1
183 adrenal cortical carcinoma 10.1 VIM MUC1 CALB2 ACTC1
184 chordoid meningioma 10.0 VIM S100A1 MUC1
185 vulvar proximal-type epithelioid sarcoma 10.0 VIM KRT5
186 syringoma 10.0 VIM S100A1 MUC1
187 bile duct mucoepidermoid carcinoma 10.0 MUC4 MUC1 KRT5
188 epididymis adenocarcinoma 10.0 WT1 THBD KRT5 CALB2
189 epididymis cancer 10.0 WT1 THBD KRT5 CALB2
190 non-langerhans-cell histiocytosis 10.0 DES ACTC1
191 sex cord-gonadal stromal tumor 10.0 WT1 VIM NKX2-1 MUC1 CALB2
192 benign metastasizing leiomyoma 10.0 VIM DES ACTC1
193 hemangioma 10.0 PDPN NKX2-1 MUC1 ACTC1
194 breast myoepithelial carcinoma 10.0 VIM KRT5 ACTC1
195 angiolipoma 10.0 VIM DES ACTC1
196 spindle cell lipoma 10.0 VIM DES ACTC1
197 metanephric adenoma 10.0 WT1 VIM MUC1 CEACAM3
198 syringocystadenoma papilliferum 10.0 MUC1 DES ACTC1
199 optic nerve glioma 10.0 VIM MUC1
200 pulmonary blastoma 10.0 NKX2-1 DES ACTC1
201 adenosarcoma 10.0 VIM DES ACTC1
202 cystadenofibroma 10.0 WT1 MUC1 KRT5 CALB2
203 pseudosarcomatous fibromatosis 10.0 VIM DES ACTC1
204 infantile myofibromatosis 10.0 VIM DES ACTC1
205 ovarian benign neoplasm 10.0 WT1 MUC1 DES CALB2
206 ovarian small cell carcinoma 10.0 WT1 MUC1 DES CALB2
207 wilms tumor 1 10.0
208 thymoma, familial 10.0
209 wilms tumor 5 10.0
210 fibrosarcoma 10.0
211 asbestos intoxication 10.0
212 myxofibrosarcoma 10.0 MUC4 MUC1 DES
213 testicular fibroma 10.0 WT1 PDPN KRT5 CALB2
214 ductal carcinoma in situ 10.0 MUC1 KRT5 CDKN2A
215 medulloepithelioma 10.0 VIM MUC1 DES CALB2
216 gliosarcoma 10.0 VIM CDKN2A ACTC1
217 glioblastoma multiforme 10.0
218 desmoplastic small round cell tumor 10.0 WT1 VIM MUC1 DES
219 apocrine adenocarcinoma 10.0 MUC1 KRT5 CEACAM3
220 alveolar soft part sarcoma 10.0 VIM DES ACTC1
221 extraskeletal ewing sarcoma 10.0 VIM NKX2-1 MUC1 DES
222 paget disease, extramammary 10.0 MUC1 KRT5 CEACAM3
223 lymphoepithelioma-like carcinoma 10.0 MUC1 KRT5 CEACAM3
224 liposarcoma 9.9 VIM DES CDKN2A CALB2
225 bile duct adenoma 9.9 VIM MUC1 CEACAM3 CDKN2A
226 ectomesenchymoma 9.9 S100A1 DES
227 desmoid tumor 9.9 DES CDKN2A ACTC1
228 endocervical adenocarcinoma 9.9 VIM MUC1 CEACAM3 CDKN2A
229 clear cell renal cell carcinoma 9.9 WT1 VIM MUC1 CALB2 BAP1
230 ewing sarcoma 9.9 WT1 VIM DES CDKN2A
231 polycystic liver disease 1 with or without kidney cysts 9.9 MUC1 CEACAM3 CALB2 ACTC1
232 papillary adenoma 9.9 VIM NKX2-1 NAPSA KRT5
233 solid adenocarcinoma with mucin production 9.9 NKX2-1 NAPSA MUC1 KRT5
234 papillary carcinoma 9.9 S100A1 NKX2-1 MUC1 CALB2
235 pneumothorax 9.9 VIM NKX2-1 MUC1 CALB2 ACTC1
236 pre-malignant neoplasm 9.9 PDPN MUC1 KRT5 CDKN2A
237 oncocytoma 9.9 VIM S100A1 NKX2-1 MUC1
238 clear cell meningioma 9.9 VIM MUC1
239 in situ carcinoma 9.9 PDPN MUC1 KRT5 CDKN2A
240 adenosquamous carcinoma 9.9 NKX2-1 MUC4 MUC1 KRT5
241 keratinizing squamous cell carcinoma 9.9 NKX2-1 NAPSA KRT5 CDKN2A
242 nephroma 9.8 WT1 MUC1 DES ACTC1
243 respiratory system benign neoplasm 9.8 NKX2-1 NAPSA KRT5 CDKN2A
244 teratoma 9.8 VIM NKX2-1 CDKN2A CALB2 ACTC1
245 cutaneous leiomyosarcoma 9.8 VIM MUC1 DES ACTC1
246 epithelioid leiomyosarcoma 9.8 VIM MUC1 DES ACTC1
247 hemangiopericytoma, malignant 9.8 VIM MUC1 DES ACTC1
248 cholangiocarcinoma 9.8 MUC4 MUC1 CEACAM3 BAP1
249 benign giant cell tumor 9.8 VIM MUC1 DES ACTC1
250 inflammatory myofibroblastic tumor 9.8 VIM MUC1 DES ACTC1
251 pancreatic ductal carcinoma 9.8 MUC1 MSLN CDKN2A
252 spiradenoma 9.8 VIM S100A1 MUC1 ACTC1
253 perineurioma 9.8 VIM S100A1 MUC1 ACTC1
254 myoepithelioma 9.7 VIM S100A1 MUC1 ACTC1
255 chondroid chordoma 9.7 VIM S100A1 MUC1 CEACAM3
256 pulmonary fibrosis, idiopathic 9.7 THBD S100A1 MUC1 ACTC1
257 chromophobe renal cell carcinoma 9.7 VIM S100A1 MUC1 CEACAM3
258 mucinous cystadenocarcinoma 9.7 VIM PDPN MUC1 CEACAM3 ACTC1
259 cystadenocarcinoma 9.7 VIM PDPN MUC1 CEACAM3 ACTC1
260 adenomatoid tumor 9.7 WT1 VIM THBD NKX2-1 KRT5 CALB2
261 rhabdoid tumor predisposition syndrome 1 9.7 WT1 VIM MUC1 DES ACTC1
262 pleural disease 9.7 MSLN CDKN2A CALB2 BAP1
263 ovary epithelial cancer 9.7 WT1 MUC1 MSLN CDKN2A
264 malignant ovarian surface epithelial-stromal neoplasm 9.7 WT1 MUC1 MSLN CDKN2A
265 adenofibroma 9.6 WT1 VIM NAPSA MUC1 CALB2 ACTC1
266 perivascular epithelioid cell tumor 9.6 NKX2-1 MUC1 DES CDKN2A ACTC1
267 pleomorphic liposarcoma 9.6 VIM MUC1 DES CDKN2A ACTC1
268 renal cell carcinoma, papillary, 1 9.6 WT1 S100A1 PDPN CDKN2A BAP1
269 pericardium cancer 9.6 WT1 MSLN KRT5 CALB2
270 rhabdomyosarcoma 9.6 WT1 VIM DES CDKN2A ACTC1
271 glomangioma 9.6 VIM S100A1 DES ACTC1
272 ischemic fasciitis 9.6 S100A1 MUC1 DES ACTC1
273 congenital fibrosarcoma 9.6 VIM S100A1 DES ACTC1
274 cutaneous fibrous histiocytoma 9.6 VIM S100A1 DES ACTC1
275 smooth muscle tumor 9.6 VIM S100A1 DES ACTC1
276 leiomyoma 9.6 VIM S100A1 DES ACTC1
277 angiomyolipoma 9.6 VIM S100A1 DES ACTC1
278 granular cell tumor 9.5 VIM S100A1 NKX2-1 DES CALB2
279 ovary adenocarcinoma 9.5 WT1 MUC1 MSLN CDKN2A CALB2
280 bile duct cancer 9.5 MUC4 MUC1 MSLN CDKN2A
281 pancreatic ductal adenocarcinoma 9.5 MUC4 MUC1 MSLN CDKN2A
282 cavernous hemangioma 9.5 VIM S100A1 NKX2-1 MUC1 DES
283 malignant biphasic mesothelioma 9.4 WT1 THBD MSLN KRT5 CALB2
284 polymorphous low-grade adenocarcinoma 9.4 VIM S100A1 MUC1 CEACAM3 ACTC1
285 liver fibroma 9.4 VIM THBD MSLN KRT5 CALB2
286 parachordoma 9.4 VIM S100A1 MUC1 DES ACTC1
287 reticulum cell sarcoma 9.4 VIM S100A1 MUC1 DES ACTC1
288 ossifying fibromyxoid tumor 9.4 VIM S100A1 MUC1 DES ACTC1
289 atypical teratoid rhabdoid tumor 9.4 VIM S100A1 MUC1 DES ACTC1
290 malignant peripheral nerve sheath tumor 9.3 WT1 VIM S100A1 MUC1 CDKN2A ACTC1
291 chondromyxoid fibroma 9.3 VIM S100A1 DES CDKN2A ACTC1
292 dermatofibrosarcoma protuberans 9.3 VIM S100A1 DES CDKN2A ACTC1
293 dedifferentiated liposarcoma 9.3 S100A1 MUC1 DES CDKN2A ACTC1
294 neurofibroma 9.3 VIM S100A1 PDPN MUC1 CDKN2A ACTC1
295 uterine carcinosarcoma 9.3 WT1 VIM S100A1 MUC1 DES CDKN2A
296 neurilemmoma 9.2 VIM S100A1 MUC1 DES CALB2 ACTC1
297 gastrointestinal stromal tumor 9.1 WT1 VIM S100A1 DES CDKN2A ACTC1
298 pleomorphic adenoma 9.1 VIM S100A1 MUC1 DES CDKN2A ACTC1
299 peritoneum cancer 9.1 WT1 MSLN KRT5 CDKN2A CALB2 BAP1
300 chordoma 9.1 VIM S100A1 MUC1 DES CEACAM3 CDKN2A
301 glomus tumor 9.0 VIM S100A1 MUC1 DES CDKN2A CALB2
302 pleural cancer 8.9 WT1 PDPN MSLN KRT5 CDKN2A CALB2
303 adenoid cystic carcinoma 8.9 VIM S100A1 PDPN MUC1 KRT5 CDKN2A
304 mucoepidermoid carcinoma 8.9 S100A1 NKX2-1 MUC4 MUC1 KRT5 CDKN2A
305 carcinosarcoma 8.5 WT1 VIM S100A1 MUC1 DES CEACAM3
306 renal cell carcinoma, nonpapillary 8.4 WT1 VIM S100A1 NKX2-1 NAPSA MUC1
307 lung cancer susceptibility 3 8.1 THBD NKX2-1 NAPSA MUC4 MUC1 MSLN

Graphical network of the top 20 diseases related to Sarcomatoid Mesothelioma:



Diseases related to Sarcomatoid Mesothelioma

Symptoms & Phenotypes for Sarcomatoid Mesothelioma

MGI Mouse Phenotypes related to Sarcomatoid Mesothelioma:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 ACTC1 BAP1 CDKN2A DES NKX2-1 PDPN
2 muscle MP:0005369 9.56 ACTC1 BAP1 CDKN2A DES PDPN S100A1
3 respiratory system MP:0005388 9.23 BAP1 CDKN2A NKX2-1 PDPN S100A1 THBD

Drugs & Therapeutics for Sarcomatoid Mesothelioma

Interventional clinical trials:

(showing 2, show less)
# Name Status NCT ID Phase Drugs
1 A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma. Completed NCT00432107 Phase 2 APO866
2 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866

Search NIH Clinical Center for Sarcomatoid Mesothelioma

Genetic Tests for Sarcomatoid Mesothelioma

Anatomical Context for Sarcomatoid Mesothelioma

MalaCards organs/tissues related to Sarcomatoid Mesothelioma:

40
Lung, T Cells, Spinal Cord, Colon, Uterus, Prostate, Testis

Publications for Sarcomatoid Mesothelioma

Articles related to Sarcomatoid Mesothelioma:

(showing 111, show less)
# Title Authors PMID Year
1
Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats. 61
32248600 2020
2
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. 61
32165206 2020
3
The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype. 61
31732616 2020
4
Pleural sarcomatoid mesothelioma with an interstitial growth pattern. 61
31898836 2020
5
Expression of V-set immunoregulatory receptor in malignant mesothelioma. 61
31363159 2020
6
Peritoneal sarcomatoid mesothelioma in a sika deer. 61
31413229 2019
7
Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature. 61
31372931 2019
8
Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence. 61
31316876 2019
9
Revisiting localized malignant mesothelioma. 61
30798074 2019
10
Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations. 61
30315275 2019
11
Impact on survival of nuclear atypia in epithelioid malignant mesothelioma. 61
31038719 2019
12
Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? 61
30278171 2019
13
[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases]. 61
30293912 2018
14
A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. 61
30429020 2018
15
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. 61
30268487 2018
16
Sarcomatoid mesothelioma of tunica vaginalis testis in the right scrotum of a dog. 61
29794371 2018
17
Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. 61
29662647 2018
18
How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab. 61
29757709 2018
19
Invasive sarcomatoid mesothelioma resulting in spinal cord compression: case report. 61
30363152 2018
20
Large primary pleural synovial sarcoma with severe dyspnea: a case report. 61
28205183 2017
21
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. 61
28782639 2017
22
Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. 61
28915695 2017
23
[Clinical and pathologic features of extrapleural sarcomatoid mesothelioma]. 61
28810297 2017
24
Primary malignant pericardial sarcomatoid mesothelioma: An autopsy report. 61
28463437 2017
25
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. 61
28128276 2017
26
Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma. 61
28704484 2017
27
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach. 61
27485167 2016
28
Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis. 61
27088640 2016
29
Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor. 61
27293862 2016
30
[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma]. 61
27210080 2016
31
Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease. 61
26108245 2016
32
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. 61
26811225 2016
33
An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. 61
26281863 2016
34
Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade. 61
27803412 2016
35
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor. 61
27660729 2016
36
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma. 61
26870271 2016
37
Infant pleuropulmonary blastoma: report of a rare case and review of literature. 61
26722577 2015
38
FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case. 61
25425731 2014
39
Reproducibility of histological subtyping of malignant pleural mesothelioma. 61
25300229 2014
40
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. 61
25217189 2014
41
Connective tissue growth factor and β-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. 61
24839947 2014
42
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. 61
24926549 2014
43
Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study. 61
24394552 2014
44
Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma. 61
25076889 2014
45
AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma. 61
24253341 2014
46
Mesothelioma and anti-Ma paraneoplastic syndrome; heterogeneity in immunogenic tumours increases. 61
23749880 2014
47
[Peritoneal malignant mesothelioma: review and recent data]. 61
24630634 2014
48
Localized biphasic type malignant mesothelioma arising in the peritoneum: Report of a case. 61
26766976 2014
49
CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. 61
24045552 2013
50
Sarcomatoid mesothelioma with osteoid differentiation. 61
23945391 2013
51
Lymphohistiocytoid mesothelioma of the pleura: a case report with cytological findings. 61
22021116 2013
52
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 61
22929121 2013
53
Primary malignant sarcomatoid mesothelioma in the pericardium. 61
23318857 2013
54
"One-stop shop" spectral imaging for rapid on-site diagnosis of lung cancer: a future concept in nano-oncology. 61
24285923 2013
55
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. 61
23270897 2013
56
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. 61
23873013 2013
57
Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors: a diagnostic pitfall. 61
22531174 2012
58
Perineal and colonic metastases in two cases of malignant mesothelioma. 61
22503285 2012
59
Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. 61
21894438 2011
60
Metastasis of a pleural mesothelioma to a hyperplastic stomach polyp: an increase of vimentin expression is seen during a gain in deciduoid morphology. 61
22355507 2011
61
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. 61
21358344 2011
62
Coarse pleural calcification in a mesothelioma patient raises the possibility of a rare tumour subtype: osteoblastic sarcomatoid mesothelioma. 61
21511743 2011
63
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. 61
21255833 2011
64
The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. 61
21969119 2011
65
Pathohistological diagnosis and differential diagnosis. 61
21479896 2011
66
TLE1 expression in malignant mesothelioma. 61
20857142 2010
67
[Sarcomatoid mesothelioma--a diagnostic challenge]. 61
20920392 2010
68
Lymphohistiocytoid mesothelioma of the pleura. 61
20618734 2010
69
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. 61
20651171 2010
70
Survey of British pathologists' performance of mesothelioma post-mortems. 61
20092958 2010
71
Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. 61
20065947 2010
72
Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. 61
20081811 2010
73
[Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: a case report and a review of the literature]. 61
19656607 2010
74
Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature. 61
19900274 2009
75
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 61
19653732 2009
76
Malignant pleural mesothelioma: clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features. 61
19627537 2009
77
Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. 61
19563663 2009
78
Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. 61
19423005 2009
79
Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. 61
19438742 2009
80
Ultrastructural and immunohistochemical analysis of fibrous long-spacing collagen fibrils in malignant mesothelioma. 61
19274581 2009
81
[A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)]. 61
19295275 2009
82
Duodenal metastasis of malignant pleural mesothelioma. 61
19129058 2008
83
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. 61
18587319 2008
84
Choroid plexus metastases from pleural sarcomatoid mesothelioma. 61
18604744 2008
85
Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases. 61
18494612 2008
86
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. 61
18199156 2008
87
Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. 61
18162779 2008
88
Biomarkers for mesothelioma. 61
17534183 2007
89
SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. 61
17507990 2007
90
D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. 61
17361207 2007
91
[Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia]. 61
17249539 2007
92
[Autopsy case of sarcomatoid malignant pleural mesothelioma]. 61
17087333 2006
93
Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. 61
16934670 2006
94
Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. 61
16366102 2005
95
Two-chamber intracardiac mesothelioma. 61
15905353 2005
96
Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. 61
15693633 2004
97
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. 61
12605647 2003
98
Peritoneal washing cytology findings of disseminated myxoid leiomyosarcoma of uterus: report of a case with emphasis on possible differential diagnosis. 61
12112816 2002
99
Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. 61
10971698 2000
100
Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. 61
10800396 2000
101
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. 61
10547583 1999
102
Pathology of diffuse malignant pleural mesothelioma. 61
9352951 1997
103
Mesenchymal chondrosarcoma of the pleura. 61
8726954 1996
104
Expression of muscle actins in diffuse mesotheliomas. 61
7538485 1995
105
Primary malignant mesothelioma of the pericardium. Case report and literature review. 61
8061543 1994
106
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases. 61
1384016 1992
107
Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case. 61
1923633 1991
108
Solitary fibrous tumor of pleura: expression of cytokeratins. 61
1708861 1990
109
Three types of spindle cell tumors of the pleura. Fibroma, sarcoma, and sarcomatoid mesothelioma. 61
3421411 1988
110
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. 61
2458647 1988
111
Tumors of serosal tissue origin. 61
3549129 1987

Variations for Sarcomatoid Mesothelioma

Expression for Sarcomatoid Mesothelioma

Search GEO for disease gene expression data for Sarcomatoid Mesothelioma.

Pathways for Sarcomatoid Mesothelioma

Pathways related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

(showing 3, show less)
# Super pathways Score Top Affiliating Genes
1 11.66 VIM PDPN MUC1 KRT5 DES BAP1
2
Show member pathways
11.37 VIM KRT5 DES
3 10.99 VIM DES ACTC1

GO Terms for Sarcomatoid Mesothelioma

Biological processes related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

(showing 4, show less)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.55 WT1 VIM NKX2-1 CDKN2A ACTC1
2 intermediate filament organization GO:0045109 9.26 VIM DES
3 actin-mediated cell contraction GO:0070252 8.96 PDPN ACTC1
4 muscle filament sliding GO:0030049 8.8 VIM DES ACTC1

Molecular functions related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

(showing 1, show less)
# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 8.8 VIM KRT5 DES

Sources for Sarcomatoid Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....